Immunity Inflammation and Disease · 2021 · 73 citations · 29 references
Life SciencesDermatologyImmunologyClinical ImmunologyInflammationMicrobiome ResearchAtopic DermatitisFecal Microbiota TransplantationGut MicrobiotaInflammatory Skin DiseasesInflammatory Skin DisordersMicrobiome TherapeuticsAtopic Dermatitis EvaluationAtopic Dermatitis ImmunopathologyAtopic Dermatitis MicrobiomeAtopic PatientsChronic Eczematous DermatitisFecal Microbiome AnalysisGut Microbiota EffectsImmune System Biomarkers
BACKGROUND: Atopic dermatitis (AD) is a remitting relapsing chronic eczematous pruritic disease. Several studies suggest that gut microbiota may influence AD by immune system regulation. METHODS: We performed the first in-human efficacy and safety assessment of fecal microbiota transplantation (FMT) for AD adult patients. All patients received 2 placebo transplantations followed by 4 FMTs each 2 weeks apart. AD severity and fecal microbiome profile were evaluated by the Scoring Atopic Dermatitis Score (SCORAD), the weekly frequency of topical corticosteroids usage, and gut microbiota metagenomic analysis, at the study beginning, before every FMT, and 1-8 months after the last FMT. RESULTS: Nine patients completed the study protocol. There was no significant change in the SCORAD score following the two placebo transplants. The average SCORAD score significantly decreased from baseline at Weeks 4-12 (before and 2 weeks after 4 times of FMT) (59.2 ± 34.9%, Wilcoxon p = .011), 50% and 75% decrease was achieved by 7 (77%) and 4 (44%) patients, respectively. At Week 18 (8 weeks after the last FMT) the average SCORAD score decreased from baseline at Week 4 (85.5 ± 8.4%, Wilcoxon p = .018), 50% and 75% decrease was achieved by 7 (77%) and 6 (66.7%) patients respectively. Weekly topical corticosteroids usage was diminished during the study and follow-up period as well. Two patients had a quick relapse and were switched to a different treatment. Two patients developed exacerbations alleviated after an additional fifth FMT. Metagenomic analysis of the fecal microbiota of patients and donors showed bacterial strains transmission from donors to patients. No adverse events were recorded during the study and follow-up period. CONCLUSIONS: FMT may be a safe and effective therapeutic intervention for AD patients, associated with transfer of specific microbial species from the donors to the patients. Further studies are required to reconfirm these results.
29
Duodenal Infusion of Donor Feces for Recurrent <i>Clostridium difficile</i>
Els van Nood, Anne Vrieze, Max Nieuwdorp et al. · New England Journal of Medicine · 2013 · 3.7K citations · Full text
Personalized Nutrition by Prediction of Glycemic Responses
David Zeevi, Tal Korem, Niv Zmora et al. · Cell · 2015 · 2.8K citations · Full text
Severity Scoring of Atopic Dermatitis: The SCORAD Index
Dermatology · 2009 · 2.3K citations
Medicine, Dermatology, Pathology +16
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Eric L. Simpson, Thomas Bieber, Emma Guttman‐Yassky et al. · New England Journal of Medicine · 2016 · 2K citations · Full text
Medicine, Dermatology, Immunology +12